doi.org/10.1093/annonc/mdz237
Original paper

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

..., Mark R. Middleton
57
Annals of Oncology56.70
Volume: 30, Issue: 12, Pages: 2013 - 2014
Published: Dec 1, 2019
Abstract
Ann Oncol 2018; 29(8): 1843–1852 (doi: 10.1093/annonc/mdy229) In the original article, there was an error in Figure 3. The figure has now been corrected as below in the online version of the article. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialAnnals of OncologyVol. 29Issue 8PreviewBevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor...
Paper Fields
Paper Details
Title
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
DOI
doi.org/10.1093/annonc/mdz237
Published Date
Dec 1, 2019
Journal
Annals of Oncology
Volume
30
Issue
12
Pages
2013 - 2014
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.